Checkpoint inhibitors (e.g., anti-PD-1 and anti-CTLA-4 antibodies) are associated with synergistic immunotoxicity when used in combination, producing higher proportions of grade 3, 4, and even 5 adverse events compared to their use as monotherapy. The gene discussed is CTLA4; the disease is immune system toxicity.